The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | KEYNOTE-177: translating results for patients and clinicians
Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the importance of the results from KEYNOTE-177 (NCT02563002) for patients with bowel cancer, and their treating physicians, including the significance of determining whether tumors are microsatellite-instability high or mismatch repair deficient. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Honoraria from Bristol-Myers Squibb, Guardant Health, Innovent Biologics, Merck KGaA, Merck Sharp and Dohme, Roche
Consultant or Advisory Role from Merck Sharp and Dohme, Roche,
Research Funding from Bristol-Myers Squibb (Inst), Gilead Sciences (Inst), Merck KGaA (Inst), Merck Sharp and Dohme (Inst), Roche (Inst)
Travel, accommodations and expenses from Innovent Biologics, Merck KGaA, Roche
